Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC
Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting
Strong financial position with approximately $490 million in cash and cash equivalents expected to fund operations into the first half of 2029
BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.
'2024 was a remarkable year for Bicara, marked by our successful transition to a public company, the advancement of our lead asset, ficerafusp alfa, and the addition of key leaders to our executive team and Board of Directors. We continue to make strong progress in 2025, with patient dosing actively underway in FORTIFI-HN01, the pivotal Phase 2/3 trial of ficerafusp alfa in recurrent/metastatic head and neck squamous cell carcinoma,' said Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics. 'As FORTIFI-HN01 progresses, we look forward to presenting updated data from our ongoing Phase 1/1b study of ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting. We also continue to evaluate the potential broad utility of ficerafusp alfa across other areas of head and neck cancer, as well as other solid tumor types.'
Pipeline Highlights
Bicara is developing ficerafusp alfa, a first-in-class, dual-action bifunctional epidermal growth factor receptor (EGFR)/transforming growth factor beta (TGF-β) antibody for multiple different solid tumor cancer types.
Pivotal Phase 2/3 Clinical Trial in 1L R/M HNSCC
In February 2025, Bicara dosed the first patients in FORTIFI-HN01, a global, randomized, double-blind, placebo-controlled, pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), excluding patients with oropharyngeal squamous cell carcinoma associated with human papillomavirus infection (HPV-positive).
Ongoing Phase 1/1b Clinical Trial in 1L R/M HNSCC
Updated data from an ongoing Phase 1/1b trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 30-June 3, 2025 in Chicago, IL.
Ongoing Phase 1/1b Expansion Cohorts and Development of Ficerafusp Alfa Across Other HNSCC Populations and Solid Tumor Types
In January 2025, Bicara presented data from the Phase 1/1b dose expansion cohort of ficerafusp alfa in combination with pembrolizumab in patients with second line (2L) or later squamous cancer of the anal canal (SCAC) at the 2025 ASCO Gastrointestinal Cancers Symposium, providing additional support for the complementary mechanisms of ficerafusp alfa and pembrolizumab.
Updated data from a Phase 1b expansion cohort evaluating ficerafusp alfa monotherapy in patients with 2L or later cutaneous squamous cell carcinoma (cSCC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will be held from April 25-30, 2025 in Chicago, IL.
A Phase 1b expansion cohort evaluating ficerafusp alfa both as monotherapy and in combination with pembrolizumab in patients with 3L+ metastatic colorectal cancer (RAS / BRAF wild type) is expected to initiate in 2025.
A Phase 1b expansion cohort evaluating ficerafusp alfa in combination with pembrolizumab in HPV-positive patients with a history of heavy smoking is expected to initiate in the first half of 2025.
Upcoming Events and Presentations
Three abstracts related to ficerafusp alfa will be presented at the upcoming AACR Annual Meeting 2025, which will be held from April 25-30, 2025 in Chicago, IL:
Dose expansion results of single agent ficerafusp alfa (BCA101), a bifunctional EGFR/TGF-β inhibitor in patients with metastatic or advanced cutaneous squamous cell carcinoma (cSCC) (Abstract #: CT034).
This presentation will highlight data from a Phase 1/1b dose expansion cohort of ficerafusp alfa monotherapy in second line or later cSCC patients.
Dual blockade of EGFR and TGF-β with ficerafusp alfa has the potential to overcome resistance mechanisms in 1L R/M HNSCC in combination with Pembrolizumab (Abstract #: 3284).
This presentation will highlight a translational medicine biomarker dataset that provides insights into the effects of targeted inhibition of TGF-β with ficerafusp alfa.
Ficerafusp alfa reverses acquired resistance to the KRAS-G12C inhibitor sotorasib in KRAS-G12C-mutated lung tumors (Abstract #: 4434).
This presentation will highlight a preclinical dataset that provides insights into the role of inhibiting TGF-β in overcoming acquired KRAS-G12C-inhibitor drug-resistant KRAS-G12C-mutated lung cancer.
Members of the Bicara management team will participate in the Stifel 2025 Virtual Targeted Oncology Forum on Tuesday, April 8, 2025 at 2:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of Bicara's website. A replay of the webcast will be archived and available following the event.
Fourth Quarter and Full Year 2024 Financial Results
Cash Position: As of December 31, 2024, Bicara had cash and cash equivalents of $489.7 million, compared to $230.4 million as of December 31, 2023. Based on its current operating and development plans, the Company expects that its existing cash and cash equivalents will fund operations into the first half of 2029.
Research and Development Expenses: Research and development expenses were $19.9 million and $63.6 million for the fourth quarter and full year ended December 31, 2024, respectively, as compared to $10.6 million and $30.6 million for the same periods in 2023. The increase was primarily due to additional costs associated with the initiation of the FORTIFI-HN01 Phase 2/3 clinical trial, as well as the Company's ongoing Phase 1/1b clinical trial to advance ficerafusp alfa.
General and Administrative Expenses: General and administrative expenses were $6.8 million and $18.8 million for the fourth quarter and full year ended December 31, 2024, respectively, as compared to $3.1 million and $9.3 million for the same periods in 2023. The increase was primarily due to additional personnel costs and professional fees to prepare Bicara to operate as a public company.
Net Loss: Net loss totaled $21.0 million and $68.0 million for the fourth quarter and full year ended December 31, 2024, respectively, as compared to $12.4 million and $52.0 million for the same periods in 2023. Net loss for the year ended December 31, 2023 included a $13.4 million non-cash expense that represents the change in fair value of Bicara's Series B preferred stock tranche rights liability.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara's lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all contain identifying words. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, Bicara's strategy, business plans and focus; express or implied statements regarding the clinical development of ficerafusp alfa, including the initiation, timing, progress and results of ongoing and planned clinical trials; the expected therapeutic potential and clinical benefits of ficerafusp alfa, including potential efficacy and tolerability; Bicara's expected operating expenses and capital expenditure requirements, including its cash runway through the first half of 2029; and participation at upcoming conferences and the timing of data readouts. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to uncertainties inherent in the development of product candidates, including the conduct of research activities and the conduct of clinical trials; uncertainties as to the availability and timing of results and data from clinical trials; whether results from prior preclinical studies and clinical trials will be predictive of the results of subsequent preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; whether Bicara's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Bicara's filings with the Securities and Exchange Commission (SEC), including Bicara's upcoming Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequent filings Bicara makes with the SEC. In addition, any forward-looking statements represent Bicara's views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Bicara intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's Investor Relations website, in addition to following the Company's press releases, SEC filings, public conference calls, presentations, and webcasts.
BICARA THERAPEUTICS INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except shares and per share data)
Three Months Ended
December 31,
Year Ended
December 31,
2024 2023 2024 2023
Operating expenses
Research and development - related party $ 816 $ 2,733 $ 8,216 $ 9,244
Research and development 19,067 7,829 55,403 21,373
General and administrative 6,754 3,125 18,770 9,272
Total operating expenses1 26,637 13,687 82,389 39,889
Loss from operations (26,637) (13,687) (82,389) (39,889)
Other (expenses) income
Interest income 5,866 1,301 14,581 1,314
Change in fair value of Series B preferred stock tranche rights liability — (49) — (13,405)
Total other income (expense) 5,866 1,252 14,581 (12,091)
Net loss before income taxes (20,771) (12,435) (67,808) (51,980)
Income tax expense (186) (5) (187) (5)
Net loss $ (20,957) $ (12,440) $ (67,995) $ (51,985)
Net Loss per share, basic and diluted $ (0.39) $ (19.71) $ (4.05) $ (89.61)
Weighted-average number common shares outstanding, basic and diluted 54,424,607 631,286 16,805,524 580,109
1 Expenses include the following non-cash stock-based compensation expense
Research & Development $ 1,040 $ 171 $ 2,084 $ 381
General and administrative 2,141 594 5,313 1,518
Total stock-based compensation expense $ 3,181 $ 765 $ 7,397 $ 1,899
BICARA THERAPEUTICS INC.
CONSOLIDATED BALANCE SHEETS
(in thousands)
December 31,
2024
December 31,
2023
Assets
Current assets:
Cash and cash equivalents $ 489,711 $ 230,440
Prepaid expenses and other assets 12,822 633
Total current assets 502,533 231,073
Property and equipment, net 155 202
Right of use asset – operating lease 690 613
Other assets 6,618 2,094
Total assets $ 509,996 $ 233,982
Liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)
Current liabilities:
Accounts payable $ 3,893 $ 2,142
Accounts payable – related party 615 1,044
Accrued expenses and other current liabilities 12,875 8,053
Accrued expenses and other current liabilities – related party — 3,561
Operating lease liability – current portion 607 285
Total current liabilities 17,990 15,085
Operating lease liability – net of current portion 131 372
Other liabilities — 17
Total liabilities 18,121 15,474
Total redeemable convertible preferred stock — 367,277
Total stockholders' equity (deficit) 491,875 (148,769)
Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit) $ 509,996 $ 233,982
Contacts
Investors
Rachel Frank
Media
Dan Budwick
1AB
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Wall Street Says Supermicro Stock Could Gain 60% in a Year
Super Micro Computer (SMCI) has weathered significant volatility in recent times, with its stock experiencing a rollercoaster ride. After reaching significant highs, the stock experienced steep declines due to a range of concerns, including allegations of accounting irregularities and a delay in filing its financial reports with the SEC. Nonetheless, SMCI stock has made an impressive recovery recently, climbing 50% year-to-date. 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio Dear Tesla Stock Fans, Mark Your Calendars for June 30 Nvidia Is Quickly Approaching a New Record High. Is It Too Late to Buy NVDA Stock? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Supermicro's stock came under heavy pressure following headlines that shook investor confidence. Allegations of accounting irregularities and a delay in filing annual reports sparked concerns about the possibility of delisting from the Nasdaq Exchange. The company eventually filed its financials, avoiding that outcome, but the damage to investor sentiment was already done. Adding to this were disappointing quarterly earnings. For its fiscal Q3 2025, Supermicro reported $4.6 billion in revenue, a 19% increase year-over-year but a 19% drop quarter-over-quarter. The results missed Wall Street's expectations, mainly due to customers holding back purchases amid uncertainty around new AI platform transitions, particularly Nvidia's (NVDA) move from Hopper to Blackwell GPU architecture. These delays contributed to the shortfall in expectations and added further pressure on the stock. These issues, however, now appear to be in the rearview mirror as those delays are beginning to turn into future growth opportunities. As customers resume spending, Supermicro appears poised to regain momentum. Furthermore, Supermicro recently announced a $20 billion partnership with Saudi Arabia-based DataVolt, which significantly boosted its stock. This deal strengthens the company's demand pipeline and will support future growth. Given these positive developments and continued investments in artificial intelligence (AI) infrastructure, SMCI stock is likely to trend higher. The highest price target for Supermicro stock is $70, courtesy of Loop Capital analyst Ananda Baruah. This target implies nearly 60% upside potential from here. Supermicro is well-positioned to benefit from secular tailwinds in the AI infrastructure market. The company specializes in building high-performance server and storage systems, many of which are now tailored specifically for AI workloads. This provides a significant runway for growth, as it strengthens the company's position to capitalize on AI demand. Thanks to the solid demand, over 70% of Supermicro's total revenue is now derived from AI GPU platforms, reflecting that the company could deliver significant growth as investments in AI continue to rise. Further, to meet the growing demand, Supermicro continues to expand its product portfolio. It has ramped up the production of its Data Center Building Block Solutions (DCBBS), which offer energy-efficient systems for next-generation computing. The company continues to roll out new products, including a range of air-cooled and liquid-cooled AI systems and racks. It has broadened its platform support to include AMD's newest AI accelerators. The expansion of SMCI's product portfolio is expected to help drive its market share higher. Supermicro is strengthening its leadership in the high-performance computing space with its technology to reduce environmental impact. The company's direct liquid cooling (DLC) technology helps lower energy costs, a critical factor as AI workloads become increasingly power-hungry. Furthermore, the rollout of its second-generation DLC-2 system will offer improved energy efficiency and thermal performance, which is expected to drive demand. Moreover, Supermicro's DCBBS reduces the time and complexity involved in building modern data centers. As the demand for scalable, plug-and-play infrastructure grows, DCBBS could become a significant growth driver for the company. The growing use of AI, which requires enhanced data center capabilities, will substantially increase demand for Supermicro's products. Supermicro's ability to design and deliver customized hardware solutions will help meet the specific needs of AI-driven workloads, strengthening its competitive positioning. Moreover, its focus on innovation, including energy-efficient green computing products and enhanced production of its DCBBS, positions it well to gain a higher market share. Analysts maintain a 'Moderate Buy' consensus rating on SMCI stock. However, given the strength of its product lineup and the booming demand in the AI and data center spaces, it wouldn't be surprising to see Supermicro's stock push toward the $70 mark in the near future. On the date of publication, Amit Singh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Business Upturn
an hour ago
- Business Upturn
Key Home Goods Unveils Limited Edition Cutting Board Collection: Where Functional Art Meets Heritage Craftsmanship
DALLAS, June 21, 2025 (GLOBE NEWSWIRE) — Key Home Goods , a design-forward brand rooted in old-world craftsmanship and modern heritage, proudly announces the release of its Signature Collection, a limited-edition series of artisan-crafted end-grain cutting boards and designer charcuterie boards that merge timeless form with everyday function. Key Home Goods Signature Collection houndstooth cutting board. Each piece in the collection is meticulously handcrafted from American hardwoods, finished with a blend of food-safe oils and waxes, and showcases the brand's distinctive proprietary houndstooth patterns, a visual hallmark that has become synonymous with Key Home Goods. With production strictly limited, every board is reserved for those who seek beauty, exclusivity, and purpose in all that they do. At the heart of this launch is Andrew Key, a seventh-generation Texan, fine woodworker, and the founder of Key Home Goods. What began in 2019 as a pair of custom end-grain cutting boards made as wedding gifts for lifelong friends has grown into a full-fledged pursuit of heirloom craftsmanship. 'I never set out to start just another cutting board company,' says Andrew. 'I wanted to create something truly extraordinary, pieces to be cherished, passed down, and appreciated for both their function and elegance.' The Signature Collection represents more than kitchen tools; it's functional art, thoughtfully designed to elevate the rituals of cooking and gathering. Each board is book-matched for visual harmony, then assembled into a composition that's as structurally resilient as it is visually stunning, honoring the heritage of end-grain cutting boards while pioneering new ground in their design. 'Every board is made slowly, with intention,' Andrew explains. 'Owning a Key Home Goods board is an invitation to savor life's richest moments. A centerpiece for gatherings and a canvas for creating memories with those you love. No two are alike, but every one is designed to be the best board you'll ever own, and the last one you'll ever need.' The Signature Collection is available exclusively at , with early access to new releases offered to registered collectors. Each board ships in custom packaging and includes access to the brand's white-glove support and timeless warranty, known as the Timeless Guarantee. Media Contact:Andrew KeyKey Home Goods [email protected]
Business Upturn
an hour ago
- Business Upturn
New Subsidiary in Mexico: SOUEAST Debuts S06 i-DM, S07, S09, Pushes Advanced New Energy Tech
By GlobeNewswire Published on June 22, 2025, 09:11 IST MEXICO CITY, June 22, 2025 (GLOBE NEWSWIRE) — On June 18, 2025, at the grand brand and products launch ceremony in Centro Citibanamex, Mexico, SOUEAST announced its entry to Mexican market and unveiled three new models, attracting wide attention, signaling a significant breakthrough in SOUEAST's Latin American expansion. SOUEAST, true to the 'EASE YOUR LIFE' philosophy, is dedicated to urban mobility with stylish, comfort, and warm-tech at its core. SOUEAST offers a diverse range of models — including SUVs and sedans — specifically designed for urban youth. (Image 1: SOUEAST Brand Launch in Mexico) Three Prominent Models Debut: Meeting Diverse Mobility NeedsAt this launch ceremony, SOUEAST introduced three urban-focused models with both fuel and hybrid power types as follows: The S06 i-DM, an urban stylish C-class hybrid SUV, focuses on sporty aesthetics and high efficiency. With its hybrid capabilities and outstanding range, its head-turning contemporary design houses advanced hybrid technology, delivering an impressive 114 km pure electric range and a combined range of over 1,000 km when fully fueled, fully meeting the diverse needs of young people for daily commuting and urban traffic congestion in Mexico. It enhances the driving experience with intelligent features including L2 autonomous driving capabilities and comprehensive smart safety systems. (Image 2: SOUEAST S06 i-DM) The S07, an urban intelligent C-class SUV, skillfully combines practicality and style for urban trendy and fun-loving youth. Beyond its stylish design and comfortable interior, it delivers intelligent features including dual 12.3-inch screens, 6-way adjustable driver seat with memory, remote start and full ADAS, offering luxury-grade connectivity and safety. The S09, a flagship smart premium D-class SUV, redefines spacious luxury with its commanding 4,858*1,925*1,780mm dimensions and 2,850mm wheelbase. Its 7-seat version catering specifically to multi-passenger needs. Powered by a robust 2.0T engine, it caters to urban users with its aesthetic design, intelligent driving, and luxurious features, embodying the brand's high standards. (Image 3: SOUEAST S07 and S09) Each model in the lineup embodies SOUEAST's 'STYLISH-COMFORT-WARM TECH' product DNA, seamlessly integrating innovative technology and exceptional quality, to meet diverse urban mobility needs with EASE. Promoting Comprehensive Localized Operations Regarding the long-term development plan for the Mexican market, SOUEAST adheres to the concept of 'In Mexico, For Mexico' and promotes a comprehensive localized business strategy. In terms of network construction, the company plans to establish 40 showrooms by the end of 2025 and expand to 50 in 2026 in Mexico, building a convenient and efficient service network through a standardized service system. On the after-sales front, preparations are underway for a regional spare parts center for Latin America. This facility will ensure 100% parts availability and enable 24-hour delivery, ensuring rapid response to customer service needs. Meanwhile, the company actively promotes the establishment of the Central and South American Research Institute. Centered on localized product development, the institute aims to introduce models that are better aligned with the preferences and needs of Mexico customers. Driving a New Journey in Latin America: Leading the Future of Green Mobility The Mexican subsidiary showcase SOUEAST's firm commitment to the Latin American market, bringing advanced new energy vehicle(NEV) technologies to Mexico. By offering smart, eco-friendly, and diverse mobility solutions for urban youth, SOUEAST is accelerating Mexico's green transition while expanding its global footprint, with plans to introduce more NEV models and reinforce its role in sustainable development worldwide. Since initiating its globalization strategy in 2024, SOUEAST has made continuous strides across key international markets. Following its global debut in Uzbekistan and rapid entry into multiple markets across the Middle East, the successful launch in Mexico marks another milestone in its growing global presence. To date, SOUEAST has entered more than 30 countries and regions, with over 144 sales and service outlets. Looking ahead, the brand aims to expand into more than 80 markets and establish over 2,000 outlets within five years—bringing the EASE Urban Lifestyle to users worldwide. Photos accompanying this announcement are available at: Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
